Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
Celgene
Manali Kamdar; Scott R Solomon; Jon Arnason; Patrick B Johnston; Bertram Glass; Veronika Bachanova; Sami Ibrahimi; Stephan Mielke; Pim Mutsaers; Francisco Hernandez-Ilizaliturri; Koji Izutsu; Franck Morschhauser; Matthew Lunning; Victor A Chow; Sandrine Montheard; Josu Santamaria; Silvia Colicino; Ken Ogasawara; Lara Stepan; Fei Fei Liu; Jeremy S Abramson